Plus, a Permian Basin play that just got a 73% PT bump, a GPCR drug developer with 60% upside potential, and more...
Plus, a precision oncology biotech with room to run, a CNS drug challenger with nearly $4B in projected peak sales, and more...
Plus, a top-1% analyst's highest-conviction AI infrastructure bet and the post-IPO software name Goldman says the market is missing out on.
Plus, a firm with three hyperscale leases signed, a biotech with four drugs on market, and a stock down 29% that activists just shook up.
Plus, a chipmaker guiding to 903% earnings growth, a gene therapy stock one top 2% analyst gives 170% upside, and more.
Plus, a quiet winner of the US defense budget, a COVID-era darling due for a resurgence, and a top-tier analyst’s contrarian call carrying more than 100% upside potential.
Plus, a beaten-down enterprise play with more than 100% upside potential, a bitcoin miner with a repositioning plan that caught the eye of a Top 1% analyst, and more.
Plus, an unexpected beneficiary of a dead deal, a post-AI-selloff dip-buying opportunity, and a high-upside-potential call from an analyst with an average return of more than 80%.
Plus, a pick to benefit from supply chain digitization by a top 1% analyst, an under-the-radar energy player, and an “easy-to-own” digital gaming name with more than 60% implied upside.
Plus, a beaten-down fintech stock with a favorable risk-reward profile, our Goldman Sachs-backed bull thesis, and Morgan Stanley’s 125% upside data center pick.
Plus, a favorite chipmaker from Wall Street’s #1-ranked analyst, a data center stock HC Wainwright sees doubling in value, and why JEF sees a bounceback for Broadcom.
Plus, a deep discount in the private warehouse club sector, a Starbucks competitor Citi sees as a sharp share gainer, and a little-known stock poised to solve a “critical” problem.
Plus, William Blair’s memory “supercycle” winner, a stock Morgan Stanley says has “ongoing execution issues”, Netflix’s new deal, the top IPOs of tomorrow, and more.
Plus, why Wells Fargo sees a turnaround for DraftKings, Morgan Stanley’s casualty of the “grocery wars”, and more.
Plus, Oppenheimer’s 'golden opportunity for a breakout', why Freedom Capital believes Venezuela oil enthusiasm is 'unjustified', a big bank going full crypto, and more.
Plus, a doubled price target from Aletheia, potential beneficiaries of the latest tariff delay, and much more.
We reviewed outlooks from a dozen bulge-bracket banks, asset managers, and global investment firms to identify the most useful takeaways for active investors like you.
Plus, the mid-cap software stock KeyBanc was wrong about, Goldman Sachs’ semiconductor double-downgrade, and much more.
Plus, dual double-downgrades, a crypto firm with 130% implied upside, and much more.
The secret sauce behind silver’s rally, Wells Fargo’s new pick for AI “super-cycle” leader, Huber Research’s grim view on the Netflix-WBD deal, and much more.
An income investment for the new rate environment, a massive IPO announcement, an 'overdone' AI selloff, and more.
A beaten-down sector quietly being transformed by AI, a firm 'uniquely positioned' within the Trump administration, and much more.
The energy tail risk no one’s talking about, why a retail giant got double-downgraded, a candidate for the next IPO pop, and more.
This week in Street Sheet Research: a six-week market rally hits a wall amid AI fatigue, Datadog barks back with post-earnings upgrades, and the U.S. redraws its critical minerals map. Plus, what Polymarket’s long-awaited U.S. debut could mean for prediction markets everywhere.
Plus, an attractive opportunity amid a 'minefield for investors', a slew of price target hikes across the crypto sector, and more.
